Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs.
Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development.
Company Details
- Employees
- 18
- Founded
- 2019
- Address
- No. 99, Lane 130, Section 1, Yanjiuyuan Rd, Nangang District, Taipei,115,taiwan, Province Of China
- Industry
- Biotechnology
- Website
- https://anbogen.com
- HQ
- Taipei
Anbogen Therapeutics Questions
Anbogen Therapeutics's website is https://anbogen.com
Anbogen Therapeutics's LinkedIn profile is https://tw.linkedin.com/company/anbogen-therapeutics
Anbogen Therapeutics has
18 employees.
View email and phone details for 18
employees at Anbogen Therapeutics.
Anbogen Therapeutics's industry is
Biotechnology
Anbogen Therapeutics's top competitors are
Plus Therapeutics, Inc.,
Anhorn Medicines,
Launxp Biomedical,
Beigene,
Abdera Therapeutics,
Psi Cro Ag,
Act Genomics,
Syneos Health,
Genscript,
Myricx Bio.
Anbogen Therapeutics's categories are Biotechnology
Anbogen Therapeutics's founding year is 2019
